jennifer porter troutman

Securing manufacturing capacity is a challenge. https://lnkd.in/g9J6J-Bg, Super excited to share my professional experience with students at Bucks County Community College. All rights reserved. Audio recording clip of interview with Dr. Porter Troutman by Claytee D Jennifer L. Porter is a partner in the Life Sciences group at Goodwin. VCard. We look forward to connecting with you! @ Trotter Review, Special Edition, 1999. LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads) on and off LinkedIn. Thank you for the opportunity and the honor of sharing with your students Stacey Bennett, Communication Studies Area Head, Arts & Communication Department. About Us| See here for a complete list of exchanges and delays. Want to see someone you know featured? She was a Legal intern for Judge Theodore McKee, United States Court of Appeals for the Third Circuit from 2006 to 2007. Third, who would be the potential SPAC sponsors? Jennifer has years of experience counseling clients in the life sciences industry through their most important strategic transactions and disclosure and governance issues. Dr. Porter Troutman, UNLV #WPW2023 Porter: The biggest issues were seeing for ATMP sponsors as we move out of the pandemic are related to manufacturing and financing. Q&A With Jennifer Porter, partner, Troutman Pepper Welcome, Joseph J. Milestones/achievements/messages? Follow TWN Jennifer Troutman - Admission - University of Evansville #philadelphia #greaterphiladelphia #mayoralelection #government #politics, The 18.5-acre farmland estate in Montgomery County has 10 different buildings on the property, including a historic home that was once a school and outbuildings used as a gym, a greenhouse, event space and even a soap-making space. They can be completed faster than a traditional IPO, but require a vote of the SPAC shareholders, and carry the same lack-of-stabilization risks post-merger. Temple Women are Everywhere!! It may be protected by copyright . She also worked on the development and implementation of a soil and groundwater management plan for over 200,000 tons of excavated materials in support of construction activities for the Betsy Ross Bridge-Aramingo Avenue Interchange Project. Jennifers representation of life sciences companies spans the corporate life cycle, including formation matters, general corporate representations and counseling, public and private securities offerings, and mergers and acquisitions. Porter: Philadelphias Cellicon Valley continues to grow. Jennifer L. Troutman's office is located at 4401 Penn Ave, Pittsburgh, PA. Follow TWN and stay connected with them all!! In addition, because SPACs are considered 'shell companies' under SEC rules, the post-merger company will be subject to increased SEC regulation, such as having to wait longer to rely on Rule 144 for resales of securities, or not being able to become a well-known seasoned issuer (WKSI) for at least three years post-merger. (magna cum laude She can be reached at jennifer.porter@troutman.com. Engage via Email. What a great honor. Dr. Porter Troutman oral history interview, 2006 November 20. As cell and gene therapy manufacturing demand is expected to continue to outpace capacity, the Discovery Labs and CBM will help support the growth of Philadelphias cell and gene therapy companies. Enhancing Multicultural Education Through Higher Education Initiatives . Join Facebook to connect with Jennifer Troutman and others you may know. Association of Childhood International Association Teacher Education, 1999/2000. We look forward to connecting with you! ACT: As we move out of the pandemic, what issues specific to ATMP sponsors are coming to the surface? Temple Women are Everywhere!! Jennifer L. Troutman, NP | Pittsburgh, PA - US News Health At present there are over 30 cell and gene therapy companies and 60 labs in the region, as well as big pharma presence from GlaxoSmithKline, Bristol Myers Squibb, Merck, Sanofi, and Johnson & Johnson. Text: 812-470-3148. One Year In, SECs Gensler Has Delivered a Rulemaking Storm, Q&A With Jennifer Porter, Partner, Troutman Pepper, Century Therapeutics, Inc. in its $242.7 million initial public offering*, Collegium Pharmaceutical, Inc. in its $143.75 million offering of senior convertible notes*, Larimar Therapeutics, Inc. in its $80.5 million underwritten public follow-on offering*, Larimar Therapeutics, Inc. in its $80 million private placement*, Ocugen, Inc. in its $100 million registered direct offering*, Ocugen, Inc. in its $53.5 million public follow-on offering*, Societal CDMO, Inc. in its $35.6 million concurrent public offerings of common and preferred stock*, Recro Pharma, Inc. in its $30.0 million underwritten public follow-on offering*, TELA Bio, Inc. in its $57 million initial public offering*, TELA Bio, Inc. in its $55.2 million underwritten public follow-on offering*, TELA Bio, Inc. in its $36.8 million underwritten public follow-on offering*, Windtree Therapeutics, Inc. in its underwritten public offering and uplisting to Nasdaq*, Zynerba Pharmaceuticals, Inc. in its $57.5 million underwritten public follow-on offering*, Zynerba Pharmaceuticals, Inc, in its $48.3 million initial public offering*, Represented underwriters in multiple equity offerings and at-the-market offerings for life sciences issuers*, Collegium Pharmaceutical in its $604 million acquisition of BioDelivery Sciences International*, Eli Lilly and Company in its acquisition of Disarm Therapeutics for up to $1.22 billion*, Collegium Pharmaceutical in its $375 million acquisition of the nucynta franchise of products from Assertio*, Chondrial Therapeutics in its reverse merger with Zafgen, Inc. to form Larimar Therapeutics, and concurrent $80 million private placement*, Renovacor, Inc. in its sale to Rocket Pharmaceuticals, Inc.*, Societal CDMO, Inc. in its $50 million acquisition of IRISYS, a San Diego-based CDMO*, Recro Pharma, Inc. in its $175 million acquisition of a phase two product candidate and a manufacturing, formulation, and development business*, Renovacor, Inc. in its merger with SPAC Chardan Healthcare Acquisitions 2 Corp. and concurrent private placement*, ALKA bello in its acquisition of Otiprio and in other acquisitions and divestitures*, Panelist, Key Strategies for Navigating Your Career , Association of Corporate Counsel (ACC) Greater Philadelphia Chapter -Womens Summit, November 16, 2022, Panelist, State of the Market: Trends and Issues in Health Care and Life Sciences Transactions, ACC Greater Philadelphia In-House Counsel Conference, May 4, 2022, Co-Author, SECs Division of Corporation Finance Revises CD&Is on Non-GAAP Financial Measures, Troutman Pepper, December 16, 2022, Co-Author, SEC Proposes Rule Amendments for Beneficial Ownership Reporting, Troutman Pepper, February 28, 2022, Co-Author, SEC Proposes Rule Changes Shortening the Securities Settlement Cycle to T+1 By March 31, 2024, Troutman Pepper , February 28, 2022, Co-Author, SEC Proposes Rule Amendments Relating to Rule 10b5-1 and Insider Trading, Troutman Pepper, December 17,2021, Co-Author, SEC Proposes Rule Amendments to Improve Disclosures Relating to Share Repurchases, Troutman Pepper, December 16, 2021. [Audio recording] Oral History Research Center, Special Collections and Archives, University Libraries, University of Nevada, Las Vegas. When expanded it provides a list of search options that will switch the search inputs to match the current selection. Following the 20202021 boom of early-stage IPOs, this is an option many currently distressed public life sciences companies are considering. CBM is the first and largest single-point cell and gene therapy Contract Development and Manufacturing complex in the world, offering plasmid, viral vector and cell therapy manufacturing as well as process development, analytical development and testing services all on one site. Finally, how important is it for the private company to acquire legacy assets from a merger partner? https://lnkd.in/g9J6J-Bg. Going Public? For Life Sciences Companies, Pivoting in a Down Market Deals Value Clients Dimension N. of Transactions Your article was successfully shared with the contacts you provided. #laborandemployment. Temple University. Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts. Jennifer has years of experience counseling clients in the life sciences industry through their most important strategic transactions and disclosure and governance issues. . Popular Topics by This Author. Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile. Join us in congratulatingJennifer Gresh, Mid-Atlantic Environmental Practice Leader at Verdantas. Jennifer Porter, a partner in Troutman Pepper's #HealthSciences Department, was recognized among the 2022 #Women of Distinction by the Philadelphia Business The University of Evansville has been a part of my life and family for more than 25 years. Jennifer Porter - Reuters Opinions expressed are those of the author. She represents life sciences companies, boards, and senior management in capital markets and M&A transactions as well as provides corporate counseling to boards of directors. FDAs Project Optimus Guidance: Highlights and Tips for Success for Oncology Drug Developers, Designing Clinical Trials for Frontotemporal Dementia, DIA Europe 2023: De-Carbonizing Your Clinical Trials. Learn more about Jason and our #Charlotte office, The Troutman Pepper #Hydropower Team will be attending and speaking at Waterpower Week in Washington, D.C. Efforts to integrate clients, systems, spaces and cultures under tight time restraints is an immense undertaking that affects populations across both firms including the #alumni networks. Applied Clinical Trials: Since January 2020, the US Food and Drug Administration (FDA) has issued ten guidance documents for gene therapy program sponsors to align with the advances in research. Rights. Troutman Pepper is a national law firm with more than 1,200 attorneys strategically located in 23 U.S. cities. Troutman Pepper Nov 2017 - Jan 2023 5 years 3 months. If the answer is "very," a reverse merger will likely be the better option. Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks. Demand for IPOs has taken a nosedive thanks to geopolitical instability, near-record levels of inflation, and rising global interest rates, leading the money raised by 2022's U.S. IPOs to be trending toward roughly 5%, of what was raised in 2021, according to EY Global IPO Trends.

South Burlington Police Blog, Sebastian Stan Teeth Before And After, Articles J